Alexandria (ARE) Q1 2026 Earnings Transcript

Alexandria Real Estate Equities reported Q1 FFO per share as adjusted of $1.73 and reaffirmed its 2026 FFO midpoint at $6.40, but cut year-end occupancy guidance to 87% from 88.5% and lowered same-property NOI guidance midpoint to down 9.5%. Leasing was weak at 647 thousand square feet, including zero public biotech leases, while occupancy fell 320 bps sequentially to 87.7% and same-property NOI declined 11.7% on a cash basis. Offsetting some pressure, the company highlighted $366 million of gains from an unsecured bond tender, $4.2 billion of liquidity, and $2.2 billion of dispositions/partial interests pending or identified.

Analysis

The key read-through is that ARE is quietly de-risking the balance sheet while admitting the operating model is still in a reset phase. That combination usually helps equity holders only after the market believes the vacancy trough is visible; right now the company is still absorbing expirations faster than it is converting leasing momentum into stabilized NOI. The biggest second-order issue is that management is effectively trading near-term occupancy for lower capital intensity and faster cash-on-cash returns, which should improve medium-term FFO quality but can keep reported growth suppressed for several quarters.

The more important signal for peers is not the lower public biotech leasing print itself, but the widening bifurcation between asset classes. Core mega-campus product with embedded optionality is attracting capital, while older, vacancy-heavy assets are being re-underwritten as either JV candidates, alt-use, or partial sales. That should support a valuation premium for the highest-quality life science platforms and pressure less differentiated owners that rely on traditional wet-lab demand and higher redevelopment capex.

A contrarian point the market may be missing: the current weakness may be less about secular lab oversupply and more about a temporary financing/regulatory bottleneck that disproportionately hits public biotech. If capital markets thaw and NIH/FDA uncertainty eases, leasing could re-accelerate quickly because the same tenants still need specialized space and are not replacing it with generic office. The risk is that 2027 expirations become a second vacancy wave before that normalization occurs, which would keep guidance revisions leaning negative for the next 2-3 quarters.

For portfolio construction, this is a stock where the equity may lag until the market gets proof that disposition proceeds and JV capital can offset occupancy drag. The better trade may be relative value: long the best-capitalized platform and short the more levered or less diversified lab landlords, rather than betting on an outright sector rebound.

Key Decisions for Investors

• Initiate a tactical long ARE only on weakness below near-term support, with a 3-6 month horizon; thesis is balance-sheet repair plus lower capital intensity, but size modestly because occupancy and 2027 expirations can keep multiple expansion capped.
• Pair trade: long ARE / short a more levered life-science REIT such as NLOP or a weaker office-lab proxy over the next 1-2 quarters; this isolates quality/financing dispersion and reduces market beta.
• Buy ARE 6-9 month puts only if leasing commentary deteriorates again or 2Q occupancy guidance is cut further; that is the clean catalyst for a second leg down as 2027 downgrades get priced in.
• Rotate into NVS or AMZN on any pullback if you want indirect exposure to the same ecosystem; both benefit from a slower, more selective capital environment while ARE's near-term operating leverage remains negative.
• Monitor for a better entry in 1-2 quarters after disclosure on JV mix and disposition cadence; if core JV capital materially lowers cost of capital, that is the point where the equity can rerate, not before.